PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03280173
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Palbociclib in Real World Practice
- Conditions
- Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- Other: non-interventional
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1285
- Registration Number
- NCT03280303
- Locations
- 🇺🇸
John Muir Clinical Research Center, Concord, California, United States
🇺🇸Baptist Health Miami Cancer Institute, Plantation, Florida, United States
🇺🇸Western Connecticut Health Network, Norwalk, Connecticut, United States
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
- Conditions
- HealthyPrimary Immune ThrombocytopeniaPolyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- Drug: PF-06755347 intravenous healthy participantDrug: Placebo intravenous healthy participantDrug: PF-06755347 subcutaneous healthy participantDrug: Placebo subcutaneous healthy participantDrug: PF-06755347 subcutaneous ITP
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 58
- Registration Number
- NCT03275740
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇧🇪Pfizer Clinical Research Unit, Brussels, Belgium
🇪🇸Hospital Universitario La Paz, Madrid, Spain
Immunization To Prevent Acute COPD Exacerbations
- Conditions
- Pneumococcal InfectionsCOPD
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 530
- Registration Number
- NCT03276754
- Locations
- 🇪🇸
Hospital Universitario Son Espases, Palma, Islas Baleares, Spain
🇪🇸Hospital el Bierzo, Ponferrada, León, Spain
🇪🇸Hospital Gregorio Marañon, Madrid, Spain
A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Biological: US-approved NeulastaBiological: PF-06881894
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 422
- Registration Number
- NCT03273842
- Locations
- 🇺🇸
Seaview A Quotient Clinical Business, Miami, Florida, United States
🇺🇸Quotient Sciences- Jacksonville, LLC, Jacksonville, Florida, United States
🇺🇸Vince & Associates Clinical Research Inc., Overland Park, Kansas, United States
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT03269695
- Locations
- 🇷🇸
Clinical Hospital Center Zvezdara - Clinic for Gastroenterology and Hepatology, Belgrade, Serbia
🇦🇺Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇮🇹ASST Rhodense - Ospedale di Circolo di Rho, Rho, Milano, Italy
Glasdegib Absolute Bioavailability Study
- Conditions
- Healthy Volunteer Study
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03270878
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
- Conditions
- MSSRAS-mutant Colorectal Cancer
- Interventions
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT03271047
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center - South County, Saint Louis, Missouri, United States
🇪🇸Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: PF-06863135 monotherapy IV or SC
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 101
- Registration Number
- NCT03269136
- Locations
- 🇺🇸
UChicago Medicine - River East, Chicago, Illinois, United States
🇺🇸UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital), La Jolla, California, United States
🇺🇸UCSD Medical Center - Vista, Vista, California, United States
Open Label Safety Study in Acute Treatment of Migraine
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3019
- Registration Number
- NCT03266588
- Locations
- 🇺🇸
FutureSearch Trials of Neurology, LP, Dallas, Texas, United States
🇺🇸Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States